Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2023

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG

Gemcitabine

Administered by intravenous infusion over 30 minutes.

DRUG

nab-paclitaxel

Administered by intravenous infusion over 30-40 minutes.

Trial Locations (1)

RECRUITING

Virginia mason medical Center, Seattle